Theseus Pharmaceuticals Inc

NASDAQ THRX

Data sourced from

and

Download Data

Theseus Pharmaceuticals Inc Current Liabilities Ratio 1 year YoY Change (%) for the year ending December 31, 2022: 241.17%

Theseus Pharmaceuticals Inc Current Liabilities Ratio 1 year YoY Change (%) is 241.17% for the year ending December 31, 2022, a 361.92% change year over year. The current liabilities ratio measures the proportion of a company's current liabilities in relation to its total assets. It is calculated by dividing current liabilities by total assets. This ratio indicates the percentage of a company's total assets that are financed by current liabilities, such as accounts payable and short-term debt. It helps assess the company's short-term solvency and its ability to meet immediate obligations. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Theseus Pharmaceuticals Inc Current Liabilities Ratio for the year ending December 31, 2022 was 0.05, a 241.17% change year over year.
Theseus Pharmaceuticals Inc Current Liabilities Ratio for the year ending December 31, 2021 was 0.01, a -92.08% change year over year.
Theseus Pharmaceuticals Inc Current Liabilities Ratio for the year ending December 31, 2020 was 0.19, a -57.04% change year over year.
Theseus Pharmaceuticals Inc Current Liabilities Ratio for the year ending December 31, 2019 was 0.43.

NASDAQ: THRX

Theseus Pharmaceuticals Inc

CEO	Dr. Iain D. Dukes D.Phil., DPHIL, M.A.
IPO Date	Oct. 7, 2021
Location	United States
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
Employees	38
Sector	Healthcare
Industry	Biotechnology

Description

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts. As of February 14, 2024, Theseus Pharmaceuticals, Inc. operates as a subsidiary of Concentra Biosciences, LLC.

Key trends